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Background & objective: Pneumocystis pneumonia (PCP) is responsible for pulmo-
nary infectionin immunocompromised patients. This study aimed toinvestigating the 
frequency of Pneumocystis colonization in patients hospitalized in the intensive care 
unit (ICU) and evaluating the relationship between PCP and Pneumocystis coloniza-
 tion.
Methods: In the current cross sectional study bronchoalveolar lavage (BAL)fluids of 
100patients were collected from surgery and neurosurgery ICUs with different under-
lying corticosteroid therapy conditions. Patients were divided into 2 groups (patients 
who receivedcorticosteroidsand not received corticosteroids). Direct examination on 
BAL fluids was performed by the Gomori methenamine silver andGiemsastaining 
techniques. Additionally, 2 filtered air samples of the 2 above mentioned unitswere 
collected. A nested-PCR targetedmtLSUrRNA gene and sequencing were used to 
identify Pneumocystis spp.
Results: In direct microscopy, 31 out of 100 hospitalized patients (31%) showed 
positive results. Twenty-three (46%) of smear positive patients were from the group 
of patients who received corticosteroid, the other 8(16%) were from the group of 
patients who didn’t receive corticosteroids (P= 0.001). Pneumocystis jirovecii DNA 
was detected in 77out of 100BAL samples by nested-PCR (77%) in which 40(52%) 
and 37(48%) samples were obtained from the patients who received and not received 
corticosteroids, respectively. Pneumocystis genome was found in 1 of the 2 filtered 
air samples.
Conclusion: A significant number of patients who received corticosteroids were also 
colonized by P. jirovecii that may predispose to PCP or be transmitted to susceptible 
patients.  A significant relationship was observed between the mean hospital stay and 
detection rate.
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Introduction
Pneumocystis spp. are eukaryotic, dimorphic, yeast-
like fungi. Among 5 Pneumocystis species, Pneu-
mocystis jirovecii is responsible for Pneumocystis 
pneumonia (PCP) in patients withimmune system 
impairments (1). 
Prevalence of human immunodeficiency virus (HIV) 
increased the rate of PCP worldwide. The use of rou-
tine prophylaxis in patients infected with HIV led to 
reduced rates of PCP in the HIV-infected population. 
Despite this decrease, it remains one of the leading 
causes of pneumonia in patients with other types of 
immunodeficiency (2-4). It is also observed in pa-
tients with cancers (particularly hematologic malig-
nancies), solid tumor, organ transplantation, and cys-
tic fibrosis. Corticosteroids, chemotherapeutic agents, 
and other immunosuppressive medications are con-
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sidered as important risk factors to develop PCP (5-
7). In patients hospitalized in the intensive care units 
(ICUs), delay in intubation and increased duration of 
mechanical ventilation are decisivefactorsthat elevate 
the rate of mortality by PCP (8-10). The respiratory 
tract of healthy people is also colonized with the mi-
croorganism (11). Pneumocystis spp. carriers serve as 
the reservoirs for the pathogen and predispose the host 
to subsequent opportunistic infections (8). Person-to-
person transmission due to air pollution and previous 
colonization of pneumocystis in patients admitted to 
ICU can play important rolesto spread infection be-
tween them. Development of PCP can intensify the 
underlying disease and complicate the therapeutic 
process for the patients. Therefore, the diagnosis of 
PCP should be considered in patients who are at risk 
for PCP. Quick assessment is very critical in immu-
nocompromised patients or the ones treated with im-
munosuppressive drugs (12,13). The current study 
aimed at investigating the frequency of pneumocystis 
spp. colonization in patients admitted to surgery and 
neurosurgery ICUs of a teaching university hospital, 
Ardabil, Iran.
 Materials and Methods
Clinical specimens
In the current cross sectional study, a total of 100 
BAL specimens were obtained during 2011 to 2014 
from patients with pulmonary discharge without any 
evidence of PCP and 50 oral washing samples from 
healthy individuals in ICU. The clinical specimens 
were collected from patients admitted to surgery and 
neurosurgery ICUs of Fatemi Hospital, affiliated to 
Ardabil University of Medical Sciences, Ardabil, 
Iran.
Fifty out of 100 patients received corticosteroids 
(dexamethasone), while the others (50 ones) received 
no corticosteroid. All of the patients underwent suc-
tion and BAL sampling as part of their ordinary 
clinical and diagnostic assessments. Oral wash-
ing samples were obtained by gargling with 20 mL 
sterile physiologic serum (0.9% NaCl) for 1 minute 
from 50 healthy volunteers. Additionally, to examine 
the presence of Pneumocystis spp.  in air, 2 filtered 
air samples of surgery and neurosurgery ICUs of the 
hospital were prepared. The study was approved by 
the Ethical Committee of Ardabil University of Medi-
cal Sciences(ID:IR.ARUMS.REC.1396162) and in-
formed consent was obtained from all study volun-
teers. 
Approximately 3-4 mL of each BAL sample was 
transferred into sterile tubes, thoroughly vortex-
mixed, and divided into 2 aliquots. Two smears 
were prepared from 1 aliquot of each specimen for 
the Giemsa and Gomori methenamine silver (GMS) 
staining for the microscopic examinations and other 
aliquotswere stored at -80ºC for polymerase chain re-
action (PCR).
Microscopic detection of pneumocystis by 
staining methods
The specimens were thoroughly mixed and centri-
fuged at 13000 g for 20 minutes;10% NaCl solution 
was applied to loosen the mucoid materials in speci-
mens if needed. The resultant pellets were used for 
direct microscopic examination and nested-PCR. For 
direct microscopic examination, smears were pre-
pared, fixed, and stained by the Gomori methenamin 
silver (GMS) and Giemsa methods. Stained smears 
were observed by 2 experienced microscopists to en-
hance the sensitivity of the method (14). 
A total of 2 air samples were collected from surgery 
and neurosurgery ICUs via the filters embedded in the 
main rooms of the units.
 A0.2-µm Millipore filter and air pump were used 
for air filtration. The filter cassette was placed about 
1.5 m from the floor, in the center of patients room. 
Nearly 3 m3 air was passed through the filter within 
2 hours, while the filters were kept humid with sterile 
distilled water during filtration. Filters were put into 
sterile falcon and transferred to laboratory and used 
for DNA extraction.
Nested-PCR
DNA was extracted using QIAamp® DNA mini 
kit (Qiagen, Hilden, Germany) according to the 
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manufacturer`s protocol. Extracted DNAs were stored 
at -20ºC until analysis.
Nested-PCR protocol targeting a conserved region 
of mtLSUrRNA was used to detect Pneumocystis spp.
 in specimens (7,15). The primer sequences for the 
initial amplification were pAZ102-H: 5´-GTGTAC-
GTTGCAAAGTACTC-3´ as forward and pA Z102-
E:5´-GATGGCTGTTTCCAAGCCCA-3´ as revers 
which resulted in a 346-bp product.
 The primers nested within the first step AZ102-
X:5′-GTGAAATACAAATCGGACTAGG-3′as for-
ward and pAZ102-Y:
5´-TCACTTAATATTAATTGGGGAGC -3´ as re-
vers were used for the second amplification reaction 
and yielded a 260-bp product (1). Each reaction mix-
ture for early PCR (final volume: 50 μL) consisted 
of 10µL 10X PCR buffer, 3 µM MgCl2, 100 µM de-
oxynucleoside triphosphates, 0.5μM primers, 5 U Tag 
DNA polymerase, 5 μL DNA template solution, and 
enough ultrapure distilled water (DNase and RNase 
free). Controls consisted of reaction mixture alone as 
negative and positive controls containing 2 μL DNA 
samples obtained from a patient with histologically 
confirmed pneumocystis (gifted from Prof. Sabin-
eSchmoldt, Max von Pettenkofer-Institutfür Hygiene 
und Medizinische, Mikrobiologie, Germany). Initial 
amplification reaction was carried out under the fal-
lowing condition:1cycle at 94°C for 4 minutes, 35 
cycles of 94˚C for 45seconds, 54˚C for 60seconds 
and 72˚C for 60 seconds, and a final extension for 
7 minutesat 72˚C. For the nested-PCR, the following 
protocol was used with 2 μL of the initial amplifica-
tion product as the template, 2 µM MgCl2 and 200 
µM deoxynucleoside triphosphates in 50 μL of reac-
tion mixture. For the second amplification: 1 cycle at 
94˚C for 4 minutes and 30 cycles at 94˚C for 45 sec-
onds, 59˚C for 45seconds, and 72˚C for 60seconds, 
followed by a final extension cycle at 72˚C for 7 min-
utes.
The amplification products were electrophoresed 
on 1.5% agarose gel, and then, stained with ethidium 
bromide to visualize the amplicon. All the positive 
bands revealed in electrophoresis were extracted (Sil-
ica Bead DNA Gel Extraction Kit, Fermentas, Lithu-
ania) using low melting point agarose  (Fermentas, 
Lithuania)and then, purified and sequenced (MWG 
DNA Sequencing Services, Germany) to identify 
Pneumocystis spp.
Statistical analysis
Data were analyzed by chi-square and ttest with 
SPSS software version 15.0. In all statistical analyses 
P <0.05 was considered significant.
Results
A total of 100 patients, 38 (38%) from neurosurgery 
ICU and 62 (62%) from surgery ICU (67 males and 33 
females) and 50 in healthy immunocompetent group 
were included in the current study. The patients were 
at the age range of 13 -87 years (mean: 43.1±21.5); 
they were divided into2 groups of patients who re-
ceived corticosteroids (50%) and not receive corti-
costeroids(50%). Dexamethasone systemically was 
administered to group of patients who received corti-
costeroidswithin a week before specimen collection. 
Corticosteroid perception ranged8 to 336 mg daily 
with an average accumulative dose of 86.22 mg. The 
mean of hospital staywas 22.7±1.54 days (ranged 7 to 
110). Hospitalization average for patients with direct 
positive microscopy was 17.4±2.2 and for patients 
with direct negative microscopy was 10.6±1.1 days 
(P=0.04), but the average of hospitalization in afore-
mentioned groups  was not significant regardingPCR 
results (13.7±1.6 vs. 9.5±1.1, respectively). 
Although 72% of the patients received 1 or more 
antibiotics,none of them had trimethoprim/sulfa-
methoxazole (TMP-SMX) in their regimen. There 
was no significant difference between the patients 
who received and not receivedantibiotics basedon the 
results of direct microscopy and nested-PCR. The re-
sults of nested-PCR and direct microscopy tests are 
summarized in Table 1. 
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ND, not detected
In direct microscopy testing, a total of 31 out of 100 
hospitalized patients (31%) showed positive results 
(Figure 1). Twenty-three (46%) of smear positive pa-
tients were from the group of patients who received 
corticosteroids, the other 8 (16%) were from the 
group of patients who did not receive corticosteroids 
(P= 0.001).The direct microscopy did not show posi-
tive results in oral washing specimens for healthy in-
dividuals.
A total of  77 (77%) out of 100 subjects showed positive 
results using nested-PCR (Figure 2). Forty-one (52%) 
of positive specimens were from the group of patients 
who received corticosteroids and 37 (48%) from the 
group of patients who did not receive corticosteroids 
(P= 0.33). There were significant correlation between 
the patients who received corticosteroids with the ac-
cumulative dose of ≥88 mg and PCR positive results 
(P=0.02); on the other hand, 100% of the patients had 
positive result in PCR. Eight (16%) out of 50 oral 
wash specimens, obtained from healthy individuals, 
showed positive nested-PCR results. There was no 
correlation between the colonization rate and gender 
or age of the patients (P >0.05). The air filtered sam-
ple collected from 1 of the ICUs gave positive result 
in nested-PCR. Sequence analysis of the nested-PCR 
products of partial mtLSUrRNA gene revealed that all 
positive specimens, except 1 (Pneumocystis carinii), 
belonged to the same Pneumocystis species, Pneumo-
cystis jirovecii.
Table 1.  Frequency of Colonization of Pneumocystis jirovecii Among the Study Groups and Healthy Individuals
Test
Patients
Healthy Individuals;N 
(%)
Patients who Received Cortico-
steroids; N (%)
Patients who did not Receive 
Corticosteroids; N (%)
Direct microscopy  23 (46)    8 (16) ND
Total 31 (31)  0 (0)
Nested-PCR 40 (52)  37 (48)  8(16)  
Total 77 (77)  11 (22)
Each group comprised of 50 cases.
Figure 1. Cyst of Pneumocystis spp. in BAL sam-
ple, stained with Giemsa
Figure 2. Nested-PCR results: Lanes 1, 2, 3, and 
4 are positive samples; Lane5: positive control; 
Lane6: negative control; Lane M: the 100-bp 
Ladder
 (Fermentase, Germany) 
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Discussion 
PCP is a seriouspneumonia that generally affects 
immunocompromised individuals. The incidence of 
PCP increases among patients receiving immunosup-
pressive medications in recent years (4,8). Upon large 
epidemiological studies, the mortality rates decreased 
in Europe in the last 2 decades, thanks to the system-
atic use of sulfa prophylaxis, adjunctive steroids (16). 
To the authors` best knowledge, the current study was 
the first on the frequency of PCP on intubated patients 
in ICU in Ardabil, Iran. The frequency of Pneumo-
cystis jirovecii colonization in healthy immunocom-
petent adults was reported 0% to 20% in different 
studies (17). In the current study, using nested-PCR, 8 
(16%) healthy individuals were colonized with Pneu-
mocystis jirovecii. 
The results of nested-PCR in the current study 
showed that the colonization rate of  Pneumocystis 
jirovecii in intubated patients admitted to ICU (77%) 
was significantly higher than that of the healthy 
individuals(n=8; 16%). Nested-PCR and direct mi-
croscopy showed 77% and 31% positive results for 
Pneumocystis jirovecii, respectively. The frequency 
of Pneumocystis jirovecii colonization in immuno-
compromised HIV-positive patients was reported 
10% to 69% and for non-HIVimmunosuppressed in-
dividuals with underlying diseases was 15.5% to 59% 
in different studies (17,18). The difference in coloni-
zation rates in different studies is largely attributed to 
the type of detection methods.
The sensitivity of direct microscopy depends on the 
organism burden in the specimen. Previous studies 
indicated that the diagnostic yield of smear stainin-
gof BAL andmicroscopic examinationis more than 
90% in individuals with comorbid HIV-PCP, while 
it is very low in non HIV-PCP patients (3,19). The 
diagnostic yield of direct microscopy was signifi-
cantly higher in the group of patients who received 
corticosteroids(n=23; 46%) in comparison with the 
ones who did not receive corticosteroids (n=8; 16%). 
This could be due to the higher burden of organism 
in the specimens obtained from the patients who re-
ceived corticosteroids.
However, there were no significant differenc-
es regarding colonization between the patients 
who received and not receivedcorticosteroids 
(P=0.33). This finding showedno significant pos-
sible association between receiving corticosteroids 
and Pneumocystis jirovecii colonization. Regardless 
of receiving corticosteroids, patients with underlying 
diseases were more susceptible to be colonized with 
Pneumocystis jirovecii than the healthy individuals. 
Despite this finding, there was a positive correlation 
between corticosteroid doses taken by patients and 
the results of Nested-PCR. It was revealed that all the 
patients that received 88 mgor more of cumulative 
doses of corticosteroids had positive results in PCR 
(P=0.002). This finding postulated that this amount 
of cumulative doses of corticosteroid may initiate the 
colonization and development of Pneumocystis spp. 
infection. Higher doses of oral corticosteroids in hos-
pitalized patients may increase the colonization risk 
of P.jirovecii as a potential agent of pneumonia in 
such individuals (8). Based on the current reports, P. 
jirovecii DNA copy numbers were significantly lower 
in the colonized patients compared with the ones with 
PCP (1.3×107vs.3.4×103copy/µL, P<0.05).
To diagnosePCP, a lower (1.6×103copy/µL) and 
upper(2×104copy/µL) cutoff value to achieve 100% 
sensitivity and specificity were determined (20). Oth-
er reports on different genes showed different cutoff 
values (21-23). 
Another approach of the current study was to exam-
ine the air samples of the ICUs for the presence of 
Pneumocystis spp. In the nested-PCR, P.jirovecii was 
detected in a sample obtained from one of the ICUs. 
Hence, the positive PCR result of filtered air sample 
postulated the possible role of spreading Pneumo-
cystis spp. from a human reservoir to the surround-
ing environment and transmitting nosocomial infec-
tions to other inpatients. Different populations such 
as patients with acute or chronic pulmonary diseases, 
pregnant females, and health care workers are at risk 
for colonization with Pneumocystis spp. In most of 
the cases, there was no sign of infection; however, 
different studies supported the idea that Pneumocys-
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tis spp. may participate in progression of underlying 
lung diseases or development of PCP (8). However, 
considering previous reports and recent animal mod-
els, transmission experiments indicated that 12 hours 
of contact between seeder and recipient was suffi-
cient for the cystic forms to be aerially transmitted 
(24, 25). The results confirmedthe study hypothesis 
about pneumocystisnosocomial transmission among 
inpatients via inhalation of Pneumocystis cysts. 
In summary, the findings demonstrated that Pneu-
mocystis spp. are the prevalent microorganisms and 
PCP is a deadly infection, especially in the absence 
of specific treatment, where as pulmonary coloniza-
tion is a less-severe presentation of Pneumocystis 
spp. infection. Therefore, it is critical to discriminate 
these 2 clinical manifestations of Pneumocystis spp. 
infection. In order to increase the specificity and sen-
sitivity of quantitative PCR assays targeting different 
genes by genomic copy number consideration, Pneu-
mocystis jirovecii burdens evaluation and diagnosis of 
Pneumocystis colonization can be useful along with 
prophylactic therapy of PCP in immunocompromised 
individuals.
Conclusion
Results of the current study demonstrated a high 
presence of P. jirovecii DNA sources in BALspeci-
mens acquired from surgery and neurosurgery ICUs. 
Also,the current study supported the concept of de-
veloping sensitive methods to detect and isolate pa-
tients colonized with Pneumocystis spp. to prevent 
organism transmission in hospitals. Use of prophylac-
tic treatmentfor immunosuppressed patients or people 
with underlying diseases and decrease in hospital 
stay declined the incidence rate of PCP and mortality 
caused by these microorganisms. Long-term hospital-
ization and medication with high doses of corticoste-
roid arevery critical in Pneumocystis spp. coloniza-
tion. It was suggested that isolation of patients under 
treatment with corticosteroid in ICU can play an 
essential role in to prevent air born transmission of 
pneumocystis. 
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